Publications

Elusys Publications

2018

descriptionDevelopment of Protective Immunity in New Zealand White Rabbits challenged with Bacillus anthracis Spores and Treated with Antibiotics and Obiltoxaximab, a Monoclonal Antibody against Protective Antigen

January 2018 – Antimicrobial Agents and Chemotherapy

2017

descriptionAnimal-to-Human Dose Translation of Obiltoxaximab for Treatment of Inhalational Anthrax Under the US FDA Animal Rule

January 2017 – Clinical and Translational Science

2016

descriptionEfficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity

October 2016 – Antimicrobial Agents and Chemotherapy

descriptionObiltoxaximab Prevents Disseminated Vacillus anthracis Infection and Improves Survival during Pre-and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax

October 2016 – Antimicrobial Agents and Chemotherapy

descriptionPharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies

September 2016 – Clinical Therapeutics

Animal to Human Dose Translation under the Animal Rule- Obiltoxaximab (ETI-204) Case Study

February 2016 – 2016 ASM Biodefense and Emerging Diseases Research Meeting

Safety, Pharmacokinetics, and Immunogenicity of Intramuscular (IM) Administration of Oblitoxaximab (ETI-204) to Healthy Humans

February 2016 – 2016 ASM Biodefense and Emerging Diseases Research Meeting

The use of meta-analysis approach to demonstrate added benefit of Obiltoxaximab (ETI-204) in treatment of inhalational anthrax

February 2016 – 2016 ASM Biodefense and Emerging Diseases Research Meeting

2015

Obiltoxaximab (ETI-204) Efficacy across a Spectrum of Disease Severity in a Trigger-to-Treat Cynomolgus Monkey Inhalational Aerosol Challenge Model of Anthrax

February 2015 – 2015 ASM Biodefense and Emerging Disease Research Meeting